Pregnancy Outcomes Between Pregnant Systemic Lupus Erythematosus Patients with Clinical Remission and Those with Low Disease Activity: A Comparative Study

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2023 Jan 2

PMID 36589601

Authors

Worawit Louthrenoo

Thananant Trongkamolthum

Nuntana Kasitanon

Antika Wongthanee

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to compare pregnancy outcomes between systemic lupus erythematosus (SLE) patients who attained clinical remission based on the Definition of Remission in SLE (DORIS) and those with lupus low disease activity based on Low Lupus Disease Activity State (LLDAS).

Patients And Methods: Between January 1993 and June 2017, a total of 90 pregnancies (one twin pregnancy) from 77 patients (mean age: 26.9±4.8 years; range, 17.9 to 37.3 years) were included in the study. The clinical remission and the LLDAS groups were modified into modified clinical remission and LLDAS groups, respectively by omitting Physician Global Assessment (PGA). The clinical SLE disease activity index (cSLEDAI) score was used for LLDAS.

Results: Pregnancies in 49 patients occurred, when they were in modified clinical remission and in 57 in modified LLDAS. There was no significant difference in demographic characteristics, disease activity, or medication received at conception between the two groups. Pregnancy outcomes were similar between the modified clinical remission and the modified LLDAS groups in terms of successful pregnancy (83.67% vs. 84.21%), full-term births (38.78% vs. 38.60%), fetal losses (16.33% vs. 15.79%), spontaneous abortions (14.29% vs. 14.04%), small for gestational age infants (18.37% vs. 19.30%), low birth weight infants (42.86% vs. 40.35%), maternal complications (46.94% vs. 49.12%), and maternal flares (36.73% vs. 40.35%). The agreement of pregnancy outcomes was very high between the two groups (91.11% agreement).

Conclusion: Pregnancy outcomes in SLE patients who achieved modified clinical remission and modified LLDAS were comparable.

References

Uribe A, Vila L, McGwin Jr G, Sanchez M, Reveille J, Alarcon G . The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004; 31(10):1934-40. View

Aranow C, Askanase A, Oon S, Huq M, Calderone A, Morand E . Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE. Ann Rheum Dis. 2020; 79(6):787-792. DOI: 10.1136/annrheumdis-2019-216753. View

Shaharir S, Maulana S, Shahril N, Mohd R, Mustafar R, Said M . Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia. Lupus. 2020; 29(10):1305-1313. DOI: 10.1177/0961203320938871. View

He W, Wei H . Maternal and fetal complications associated with systemic lupus erythematosus: An updated meta-analysis of the most recent studies (2017-2019). Medicine (Baltimore). 2020; 99(16):e19797. PMC: 7440247. DOI: 10.1097/MD.0000000000019797. View

Kwok L, Tam L, Zhu T, Leung Y, Li E . Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus. 2011; 20(8):829-36. DOI: 10.1177/0961203310397967. View

Buyon J, Kim M, Guerra M, Laskin C, Petri M, Lockshin M . Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015; 163(3):153-63. PMC: 5113288. DOI: 10.7326/M14-2235. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Gladman D, Ibanez D, Urowitz M . Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. View

Lateef A, Petri M . Systemic Lupus Erythematosus and Pregnancy. Rheum Dis Clin North Am. 2017; 43(2):215-226. DOI: 10.1016/j.rdc.2016.12.009. View

10.

Andreoli L, Bertsias G, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N . EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2016; 76(3):476-485. PMC: 5446003. DOI: 10.1136/annrheumdis-2016-209770. View

11.

Tani C, Zucchi D, Haase I, Larosa M, Crisafulli F, Strigini F . Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology (Oxford). 2021; 60(12):5610-5619. DOI: 10.1093/rheumatology/keab155. View

12.

Zhan Z, Yang Y, Zhan Y, Chen D, Liang L, Yang X . Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus. PLoS One. 2017; 12(4):e0176457. PMC: 5404768. DOI: 10.1371/journal.pone.0176457. View

13.

Sen M, Kurl A, Khosroshahi A . Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy. Lupus. 2021; 30(9):1509-1514. DOI: 10.1177/09612033211021163. View

14.

Kalok A, Cader R, Indirayani I, Abdul Karim A, Shah S, Mohamed Ismail N . Pregnancy outcomes in systemic lupus erythematosus (SLE) women. Horm Mol Biol Clin Investig. 2019; 40(3). DOI: 10.1515/hmbci-2019-0007. View

15.

Chen D, Lao M, Zhang J, Zhan Y, Li W, Cai X . Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study. J Immunol Res. 2018; 2018:2413637. PMC: 6140277. DOI: 10.1155/2018/2413637. View

16.

Bitencourt N, Bermas B . Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Paediatr Drugs. 2018; 20(6):511-521. DOI: 10.1007/s40272-018-0312-2. View

17.

Petri M, Magder L . Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2018; 70(11):1790-1795. PMC: 6203602. DOI: 10.1002/art.40571. View

18.

Buyon J, Petri M, Kim M, Kalunian K, Grossman J, Hahn B . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005; 142(12 Pt 1):953-62. DOI: 10.7326/0003-4819-142-12_part_1-200506210-00004. View

19.

Kim J, Jung J, Kim H, Yang J, Kwak D, Suh C . Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients With Systemic Lupus Erythematosus. J Rheumatol. 2020; 48(5):707-716. DOI: 10.3899/jrheum.200802. View

20.

Wu J, Zhang W, Ma J, Bao C, Liu J, Di W . Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study. BMJ Open. 2019; 9(2):e023849. PMC: 6377554. DOI: 10.1136/bmjopen-2018-023849. View